{"entity":{"id":"ajcc-prognostic-stage-breast","kind":"term","name":"AJCC 8th edition prognostic stage for breast cancer","aka":["Prognostic stage group","Clinical prognostic stage","Pathological prognostic stage","Anatomic stage versus prognostic stage","AJCC 8th edition breast"],"tldr":"Since 2018 the American staging system gives breast cancer two stages: the anatomic stage from tumour size, nodes and spread, and a prognostic stage that also counts grade and the three receptors. Because triple-negative cancers are usually grade 3 and receptor negative, their prognostic stage is often a step higher than their anatomic stage; UK pages and NICE quote the anatomic TNM stage.","summary":"The eighth edition of the American Joint Committee on Cancer TNM classification for breast cancer, prepared by a multidisciplinary panel, kept the anatomic TNM stage so the system stays usable worldwide, but recognised the prognostic influence of grade, oestrogen and progesterone receptor expression and HER2 amplification and mandated their inclusion, and acknowledged gene expression panels: tumour biomarkers and a low Oncotype DX recurrence score can alter the stage, giving a flexible platform that will be updated online (Giuliano 2017). Validation in 3,327 patients with stage I to IIIC disease treated with surgery first at MD Anderson (2007 to 2013) found the prognostic stage moved 29.5 percent of patients up and 28.1 percent down relative to the anatomic stage, and stratified disease-specific survival better (C index 0.8357 against 0.737); in 54,727 patients in the California Cancer Registry (2005 to 2009) it upstaged 31.0 percent and downstaged 20.6 percent and again performed better (C index 0.8426), supporting its use (Weiss 2018). Patients treated with neoadjuvant systemic therapy were excluded from that validation, which matters for triple-negative disease, where most stage II and III patients now have chemotherapy first and the response at surgery (pathological complete response or residual cancer burden) is the stronger prognostic marker. Cancer Research UK describes the TNM 8th edition and the number stages in plain words and notes that the TNM system is the commonest way to stage breast cancer in the UK, with staging confirmed after surgery; UK clinicians do not usually quote the prognostic stage group.","asOf":"2026-09-24","wikipedia":"https://en.wikipedia.org/wiki/Breast_cancer_classification","links":[{"label":"Giuliano, CA Cancer J Clin 2017: major changes in the AJCC 8th edition breast cancer staging manual","url":"https://doi.org/10.3322/caac.21393"},{"label":"Weiss, JAMA Oncol 2018: validation of the AJCC 8th edition prognostic stage against the anatomic stage","url":"https://doi.org/10.1001/jamaoncol.2017.4298"},{"label":"CRUK: TNM staging of breast cancer","url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-grades/tnm-staging"},{"label":"CRUK: number stages of breast cancer","url":"https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-grades/number-stages"},{"label":"Royal College of Pathologists G148: dataset for histopathological reporting of breast disease in surgical excision specimens of breast cancer, version 3, November 2024 (full review due November 2026)","url":"https://www.rcpath.org/resourceLibrary/g148-dataset-for-histopathological-reporting-of-breast-disease-in-surgical-excision-specimens-of-breast-cancer.html"},{"label":"Brierley et al., International Journal of Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change (breast: the classification remains unchanged, the yp classification is clarified)","url":"https://doi.org/10.1002/ijc.70561"}],"tags":["breast","tnbc"],"related":["tnm-breast-cancer-editions"],"cancers":["tnbc","breast-cancer","breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["tnm-staging","tumour-grade","pcr","rcb","tnm-breast-cancer-editions","grade-stage-receptor-breast"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Why a UK report does not carry it. The Royal College of Pathologists dataset in force stages against UICC TNM 8, reprints it as its own appendix, and warns that 'it is recommended to use UICC TNM 8 (not AJCC TNM 8) as there are significant differences between the two staging systems'. NICE NG101 names neither edition nor the prognostic stage. The ninth edition of UICC TNM, in force from 1 January 2026, leaves the breast classification unchanged and clarifies only the post-treatment yp classification (Brierley 2026)."],"category":"Clinic basics"},"route":"/terms/ajcc-prognostic-stage-breast/","neighbours":{"term":[{"id":"tumour-grade","kind":"term","name":"Grade","route":"/terms/tumour-grade/"},{"id":"grade-stage-receptor-breast","kind":"term","name":"Grade, stage and receptor status: three different things on one breast report","route":"/terms/grade-stage-receptor-breast/"},{"id":"ki-67-in-tnbc","kind":"term","name":"Ki-67 in triple-negative breast cancer","route":"/terms/ki-67-in-tnbc/"},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/"},{"id":"rcb","kind":"term","name":"Residual cancer burden (RCB)","route":"/terms/rcb/"},{"id":"tnm-staging","kind":"term","name":"TNM staging","route":"/terms/tnm-staging/"},{"id":"tnm-breast-cancer-editions","kind":"term","name":"Which staging edition a breast report uses: UICC TNM 8, TNM 9 and the AJCC prognostic stage","route":"/terms/tnm-breast-cancer-editions/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}]}}